performed a quantitative analysis and demonstrated that the concurrent use of PPIs contributed to a marginally significant 18% increase in all-cause mortality in CRC patients receiving fluorouracil-based regimens; conversely, PPI use had little influence on the survival of patients receiving capecitabine-based therapy [ 83 ].
← all excerpts
Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance.
1
—
—